Research programme: anti-cancer therapeutics - IMV/PCI Biotech
Alternative Names: Nucleic acid therapeutics - IMV/PCI BiotechLatest Information Update: 28 Jun 2022
At a glance
- Originator IMV; PCI Biotech
- Class Antineoplastics; Nucleic acids
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Cancer
Most Recent Events
- 28 Jun 2022 No recent reports of development identified for preclinical development in Cancer in Canada
- 28 Jun 2022 No recent reports of development identified for preclinical development in Cancer in Norway
- 24 May 2018 PCI Biotech enter into a preclinical research collaboration with IMV to develop cancer therapeutics